Clinical trial · Observational
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
NCT05817227CI-TRIAL-00099449SelebrecrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is multicentric, spontaneous, observational, retrospective and prospective study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Use of immunohistochemistry investigation (IHC)
- timeFrame
- 3 years
- description
- In the retrospective part of the study, Tissue Microarrays (TMA) will be prepared from surgical samples of breast tissue from a series of patients with TNBC type breast cancer. The expression of some of the twenty-five selenoproteins will be evaluated by immunohistochemical investigation (IHC) on the TMA (Tumor Microarrays).
- measure
- Prospective evaluation of expression of some selenoproteins by kit ELISA in plasma samples
- timeFrame
- 3 years
- description
- In the prospective part of the study will be evaluated the expression of some selenoproteins by ELISA in plasma samples obtained from up to 100 healthy subjects and about 300 (\~100 per year) patients with basally metastatic TNBC breast cancer (150) and metastatic (150) before any treatment.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * TNBC breast cancer patients, before any drug treatment * healthy women aged 25-60 Exclusion Criteria: * donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.
References
Publications (22)
- BACKGROUNDSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8. PMID 30620402
- BACKGROUNDDeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2. PMID 31577379
- BACKGROUNDGarrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019 Feb;9(2):176-198. doi: 10.1158/2159-8290.CD-18-1177. Epub 2019 Jan 24. PMID 30679171
- BACKGROUNDLu J, Holmgren A. Selenoproteins. J Biol Chem. 2009 Jan 9;284(2):723-7. doi: 10.1074/jbc.R800045200. Epub 2008 Aug 29. PMID 18757362
- BACKGROUNDShort SP, Williams CS. Selenoproteins in Tumorigenesis and Cancer Progression. Adv Cancer Res. 2017;136:49-83. doi: 10.1016/bs.acr.2017.08.002. PMID 29054422
- BACKGROUNDMarciel MP, Hoffmann PR. Selenoproteins and Metastasis. Adv Cancer Res. 2017;136:85-108. doi: 10.1016/bs.acr.2017.07.008. Epub 2017 Sep 1. PMID 29054423
- BACKGROUNDAvery JC, Hoffmann PR. Selenium, Selenoproteins, and Immunity. Nutrients. 2018 Sep 1;10(9):1203. doi: 10.3390/nu10091203. PMID 30200430
- BACKGROUNDVarlamova EG. Participation of selenoproteins localized in the ER in the processes occurring in this organelle and in the regulation of carcinogenesis-associated processes. J Trace Elem Med Biol. 2018 Jul;48:172-180. doi: 10.1016/j.jtemb.2018.04.005. Epub 2018 Apr 3. PMID 29773177